当前位置: 首页 >> 检索结果
1781. Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation.
作者: Kasper Bonnesen.;Uffe Heide-Jørgensen.;Diana H Christensen.;Timothy L Lash.;Sean Hennessy.;Anthony Matthews.;Lars Pedersen.;Reimar W Thomsen.;Morten Schmidt.
来源: Circulation. 2024年150卷18期1401-1411页
Empagliflozin and dapagliflozin have proven cardiovascular benefits in people with type 2 diabetes at high cardiovascular risk, but their comparative effectiveness is unknown.
1782. Restrictive Versus Liberal Transfusion in Patients With Type 1 or Type 2 Myocardial Infarction: A Prespecified Analysis of the MINT Trial.
作者: Andrew P DeFilippis.;J Dawn Abbott.;Brandon M Herbert.;Marnie H Bertolet.;Bernard R Chaitman.;Harvey D White.;Andrew M Goldsweig.;Tamar S Polonsky.;Rajesh Gupta.;Caroline Alsweiler.;Johanne Silvain.;Pedro G M de Barros E Silva.;Graham S Hillis.;Benoit Daneault.;Meechai Tessalee.;Mark A Menegus.;Sunil V Rao.;Renato D Lopes.;Paul C Hébert.;John H Alexander.;Maria M Brooks.;Jeffrey L Carson.;Shaun G Goodman.; .
来源: Circulation. 2024年150卷23期1826-1836页
The MINT trial (Myocardial Ischemia and Transfusion) raised concern for harm from a restrictive versus liberal transfusion strategy in patients with acute myocardial infarction (MI) and anemia. Type 1 and type 2 MI are distinct pathophysiologic entities that may respond differently to blood transfusion. This analysis sought to determine whether the effects of transfusion varied among patients with a type 1 or a type 2 MI and anemia. The authors hypothesized that the liberal transfusion strategy would be of greater benefit in type 2 than in type 1 MI.
1783. Proteomics Identify Clinical Phenotypes and Predict Functional Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF.
作者: Christopher R deFilippi.;Palak Shah.;Sanjiv J Shah.;Wendimagegn Alemayehu.;Carolyn S P Lam.;Javed Butler.;Lothar Roessig.;Christopher M O'Connor.;Cynthia M Westerhout.;Paul W Armstrong.; .
来源: Circ Heart Fail. 2024年17卷9期e011792页
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome that may emerge from overlapping systemic processes associated with comorbidities. We assessed whether unique clusters of circulating proteins are associated with specific clinical characteristics and functional status at baseline and follow-up in a well-phenotyped cohort of patients with HFpEF.
1784. Transient Inhibition of Translation Improves Cardiac Function After Ischemia/Reperfusion by Attenuating the Inflammatory Response.
作者: Christoph Hofmann.;Adrian Serafin.;Ole M Schwerdt.;Johannes Fischer.;Florian Sicklinger.;Fereshteh S Younesi.;Nikole J Byrne.;Ingmar S Meyer.;Ellen Malovrh.;Clara Sandmann.;Lonny Jürgensen.;Verena Kamuf-Schenk.;Claudia Stroh.;Zoe Löwenthal.;Daniel Finke.;Etienne Boileau.;Arica Beisaw.;Heiko Bugger.;Mandy Rettel.;Frank Stein.;Hugo A Katus.;Tobias Jakobi.;Norbert Frey.;Florian Leuschner.;Mirko Völkers.
来源: Circulation. 2024年150卷16期1248-1267页
The myocardium adapts to ischemia/reperfusion (I/R) by changes in gene expression, determining the cardiac response to reperfusion. mRNA translation is a key component of gene expression. It is largely unknown how regulation of mRNA translation contributes to cardiac gene expression and inflammation in response to reperfusion and whether it can be targeted to mitigate I/R injury.
1785. Clinical Characteristics and Outcomes of Patients Suffering Acute Decompensated Heart Failure Complicated by Cardiogenic Shock.
作者: Christos P Kyriakopoulos.;Konstantinos Sideris.;Iosif Taleb.;Eleni Maneta.;Rana Hamouche.;Eleni Tseliou.;Chong Zhang.;Angela P Presson.;Elizabeth Dranow.;Kevin S Shah.;Tara L Jones.;James C Fang.;Josef Stehlik.;Craig H Selzman.;Matthew L Goodwin.;Joseph E Tonna.;Thomas C Hanff.;Stavros G Drakos.
来源: Circ Heart Fail. 2024年17卷9期e011358页
Cardiogenic shock (CS) can stem from multiple causes and portends poor prognosis. Prior studies have focused on acute myocardial infarction-CS; however, acute decompensated heart failure (ADHF)-CS accounts for most cases. We studied patients suffering ADHF-CS to identify clinical factors, early in their trajectory, associated with a higher probability of successful outcomes.
1786. Classification of Premature Ventricular Contractions in Athletes During Routine Preparticipation Exams.
作者: Sofia E Gomez.;Marco V Perez.;Matthew T Wheeler.;David Hadley.;Calvin E Hwang.;Andrea Kussman.;Daniel S Kim.;Victor Froelicher.
来源: Circ Arrhythm Electrophysiol. 2024年17卷9期e012835页
Large-scale data on incidental premature ventricular contraction (PVC) prevalence and morphologies have been lacking, leaving many providers without guidance on further cardiac testing for patients with incidental PVCs on ECG. Athletes offer an intriguing cohort to understand the clinical significance, prevalence, and common morphologies of incidental PVCs because they often undergo ECG screening during preparticipation exams.
1788. Elimination of Epicardial Scar-Related Ventricular Tachycardia With Endocardial Pulsed Field Ablation: First Clinical Report.
作者: Jose Aguilera.;Edmond Obeng-Gyimah.;Yuki Kuramochi.;Roy Chung.;Hubert Cochet.;Megan Christie.;Hiroshi Nakagawa.;Jakub Sroubek.;Oussama Wazni.;Pasquale Santangeli.
来源: Circ Arrhythm Electrophysiol. 2024年17卷10期e012992页 1789. Whole-Heart Histological and Electroanatomic Assessment of Postinfarction Cardiac Magnetic Resonance Imaging Scar and Conducting Channels.
作者: Kasun De Silva.;Timothy Campbell.;Richard G Bennett.;Robert D Anderson.;Chris Davey.;Alexandra K O'Donohue.;Aaron Schindeler.;Samual Turnbull.;Dinesh Selvakumar.;Ashwin Bhaskaran.;Yasuhito Kotake.;Chi-Jen Hsu.;James J H Chong.;Eddy Kizana.;Saurabh Kumar.
来源: Circ Arrhythm Electrophysiol. 2024年17卷9期e012922页
Cardiac magnetic resonance imaging (CMR)-defined ventricular scar and anatomic conduction channels (CMR-CCs) offer promise in delineating ventricular tachycardia substrate. No studies have validated channels with coregistered histology, nor have they ascertained the histological characteristics of deceleration zones (DZs) within these channels. We aimed to validate CMR scar and CMR-CCs with whole-heart histology and electroanatomic mapping in a postinfarction model.
1790. Eosinophilic Myocarditis in a Patient With Systemic Lupus Erythematosus and P-Neutrophil Cytoplasmic Antibodies Associated Vasculitis Overlap.
作者: Roger Winters.;Alex Grubb.;Ramon Eldermire.;Erin McGuinn.;Natasha Altman.;William K Cornwell.
来源: Circ Heart Fail. 2024年17卷9期e011612页 1791. Myocardial DNA Damage Is Responsible for the Relationship Between Genotype and Reverse Remodeling in Patients With Dilated Cardiomyopathy.
作者: Zhehao Dai.;Toshiyuki Ko.;Shunsuke Inoue.;Seitaro Nomura.;Kanna Fujita.;Kenji Onoue.;Yuki Kuramoto.;Yoshihiro Asano.;Manami Katoh.;Shintaro Yamada.;Mikako Katagiri.;Bo Zhang.;Takanobu Yamada.;Tuolisi Heryed.;Kosuke Sawami.;Takahiro Jimba.;Nanase Hori.;Masayuki Kubota.;Masamichi Ito.;Eisuke Amiya.;Masaru Hatano.;Norifumi Takeda.;Hiroyuki Morita.;Yoshihiko Saito.;Norihiko Takeda.;Issei Komuro.
来源: Circ Heart Fail. 2024年17卷11期e011879页 1792. Coronary Vasospasm During Isthmus Pulsed Field Ablation With Wide Area Focal Catheter.
作者: Alvise Del Monte.;Domenico Giovanni Della Rocca.;Luigi Pannone.;Giampaolo Vetta.;Ioannis Doundoulakis.;María Cespón Fernández.;Lorenzo Marcon.;Cinzia Monaco.;Antonio Sorgente.;Gezim Bala.;Erwin Ströker.;Juan Sieira.;Alexandre Almorad.;Andrea Sarkozy.;Carlo de Asmundis.;Gian-Battista Chierchia.
来源: Circ Arrhythm Electrophysiol. 2024年17卷10期e012923页 1793. Outcomes of Atrial Fibrillation Ablation in Heart Failure Subtypes.
作者: Arwa Younis.;Chadi Tabaja.;Pasquale Santangeli.;Hiroshi Nakagawa.;Joseph Sipko.;Ruth Madden.;Patricia Bouscher.;Tyler Taigen.;Koji Higuchi.;Katsuhide Hayashi.;Abdel Hadi El Hajjar.;Fatimah Chamseddine.;Thomas Callahan.;David O Martin.;Shady Nakhla.;Mohamed Kanj.;Jakub Sroubek.;Justin Z Lee.;Walid I Saliba.;Oussama M Wazni.;Ayman A Hussein.
来源: Circ Arrhythm Electrophysiol. 2024年17卷9期e012926页
Catheter ablation (CA) improves clinical outcomes in patients with atrial fibrillation (AF) and heart failure (HF) with reduced ejection fraction (HFrEF). We aimed to evaluate the impact of CA on clinical and quality-of-life outcomes across HF subtypes.
1794. Electrocardiogram-Based Artificial Intelligence to Discriminate Cardioembolic Stroke and Stratify Risk of Atrial Fibrillation After Stroke.
作者: Shaan Khurshid.;Samuel F Friedman.;Shinwan Kany.;Rahul Mahajan.;Ashby C Turner.;Steven A Lubitz.;Mahnaz Maddah.;Patrick T Ellinor.;Christopher D Anderson.
来源: Circ Arrhythm Electrophysiol. 2024年17卷10期e012959页 1795. Analysis of the PARAGON-HF Study Results Using Win Ratio.
作者: Minjae Yoon.;Wonse Kim.;Woong Kook.;Jin Joo Park.;Barry Greenberg.
来源: Circ Heart Fail. 2024年17卷9期e011860页
The PARAGON-HF study (Prospective Comparison of ARNI With ARB Global Outcomes in Heart Failure With Preserved Ejection Fraction) investigated the effect of sacubitril-valsartan in heart failure (HF) with preserved ejection fraction. The results, which were analyzed using conventional statistical methods, did not find a significant reduction in the primary composite end point of cardiovascular death and total hospitalization for HF. Recent clinical trials used win ratio statistics that enable the incorporation of multiple outcome aspects into the primary end point and can detect positive outcomes with fewer patients. In this study, we assessed the effect of sacubitril-valsartan on outcomes using the win ratio to analyze results from patients included in the PARAGON-HF study.
1797. 2024 ACC/AHA Key Data Elements and Definitions for Social Determinants of Health in Cardiology: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Data Standards.
作者: Alanna A Morris.;Frederick A Masoudi.;Abdul R Abdullah.;Amitava Banerjee.;LaPrincess C Brewer.;Yvonne Commodore-Mensah.;Peter Cram.;Sarah C DeSilvey.;Anika L Hines.;Nasrien E Ibrahim.;Elizabeth A Jackson.;Karen E Joynt Maddox.;Amgad N Makaryus.;Ileana L Piña.;Carla Patricia Rodriguez-Monserrate.;Véronique L Roger.;Fran F Thorpe.;Kim A Williams.
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷10期e000133页 1799. Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia.
作者: Tulsi R Damase.;Roman Sukhovershin.;Biana Godin.;Khurram Nasir.;John P Cooke.
来源: Circulation. 2024年150卷9期724-735页
Familial hypercholesterolemia (FH) is a genetic disease that leads to elevated low-density lipoprotein cholesterol levels and risk of coronary heart disease. Current therapeutic options for FH remain relatively limited and only partially effective in both lowering low-density lipoprotein cholesterol and modifying coronary heart disease risk. The unique characteristics of nucleic acid therapies to target the underlying cause of the disease can offer solutions unachievable with conventional medications. DNA- and RNA-based therapeutics have the potential to transform the care of patients with FH. Recent advances are overcoming obstacles to clinical translation of nucleic acid-based medications, including greater stability of the formulations as well as site-specific delivery, making gene-based therapy for FH an alternative approach for treatment of FH.
1800. BMI1 Inhibition Improves Lesion Burden in Cerebral Cavernous Malformations.
作者: Mariaelena Valentino.;Matteo Malinverno.;Claudio Maderna.;Van-Cuong Pham.;Claudia Jasmin Rödel.;Federica Zanardi.;Maximiliano Arce.;Lorenzo Drufuca.;Grazisa Rossetti.;Peetra U Magnusson.;Maria Grazia Lampugnani.;Elisabetta Dejana.;Salim Abdelilah-Seyfried.;Massimiliano Pagani.
来源: Circulation. 2024年150卷9期738-741页 |